GlaxoSmithKline to acquire Human Genome Sciences for $3.6 billion
LONDON — British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.
The deal, worth $14.25 per share, would give GSK full ownership of the lupus drug Benlysta (belimumab), as well as albiglutide, an experimental drug for diabetes, and darapladib, an experimental heart disease drug.
"We are pleased to have reached a mutually beneficial agreement with HGS on friendly terms and believe the combination of GSK and HGS represents clear financial and strategic logic for both companies and our respective shareholders," GSK CEO Andrew Witty said. "The transaction meets GSK’s strict financial criteria for acquisitions and, we expect, will deliver significant returns over the long term."
RediClinic offers $10 discount on school physicals via Facebook promotion
HOUSTON — Retail-based clinic operator RediClinic is gearing up for the back-to-school season by offering $10 off a school physical for those who “like” RediClinic on Facebook.
The teen health package, which is $49 with the $10 coupon, includes a physical exam, which is required for participation in sports and other school activities, an acne consultation and immunization review. As part of the immunization review, RediClinic clinician will review a teen’s immunization history, indicate which vaccines he/she may need for school admission and administer the vaccines, if necessary. Certain immunizations are required for the 2012-2013 school year.
RediClinic operates 29 clinics within H-E-B stores in the greater Houston, Austin and north San Antonio areas.
Catalina report: Simple demographic targeting on national advertising misses the mark
ST. PETERSBURG, Fla. — Simple demographic targeting does not weight advertising exposures toward households that have greater purchasing value, according to a study by Catalina Marketing released Monday. The study shows that, for a cross-section of major consumer brands, an average of just 15% of television ad exposures reach the households that account for 80% of sales. Meanwhile, brand advertisers deliver 64% of exposures to households that account for just 2% of sales.
"We undertook this study at the request of customers who wanted to better understand how demographic targeting improved delivery against their most valuable buyer segments," stated Todd Morris, EVP for Catalina. "Our findings show that demo-based targeting significantly under delivers against the most valuable buyer groups. Across $415 million in TV media spending by 10 mega-brands, ad exposures were delivered to every buyer audience in proportion to its size of population, not its value to the brand or the category."
Among important study highlights:
Demo-based TV media plans treat all buyer groups equally, no matter what their value to a brand. As a result, heavy category buyers, who spent almost five times more than the average household, received just 3% more exposures;
The average brand in the study delivered 30% of exposures to households that were inactive in their category, meaning they never bought the category or bought just one time throughout the 12-month study period; and
A majority of sales volume falls outside of common demographic targets. More than half (53%) of sales for the average brand fell outside of the demographic target (households headed by women between ages 25 years and 54 years).
According to the report, advertisers have relevant and actionable insights than demographics by which to target consumers on a mass scale. Among these new models is purchase-based audience buying, in which actual shopper data is used to determine the consumers and buyer audiences that receive advertising from brands.